Realcan Pharmaceutical Group Co Stock | 002589.SZ | CNE1000013X5 |

Date	Realcan Pharmaceutical Group Co Price
10/16/2024	2.94 undefined
10/15/2024	2.93 undefined
10/14/2024	3.10 undefined
10/11/2024	2.92 undefined
10/10/2024	2.92 undefined
10/9/2024	3.02 undefined
10/8/2024	3.19 undefined
9/30/2024	2.90 undefined
9/27/2024	2.64 undefined
9/26/2024	2.56 undefined
9/25/2024	2.47 undefined
9/24/2024	2.42 undefined
9/23/2024	2.31 undefined
9/20/2024	2.35 undefined
9/19/2024	2.37 undefined
9/18/2024	2.30 undefined

Date	Realcan Pharmaceutical Group Co Revenue	Realcan Pharmaceutical Group Co EBIT	Realcan Pharmaceutical Group Co Net Income
2023	8.03 B undefined	-11.9 M undefined	20.32 M undefined
2022	12.31 B undefined	-412.75 M undefined	-1.83 B undefined
2021	21.06 B undefined	756.78 M undefined	131.18 M undefined
2020	27.2 B undefined	1.33 B undefined	261 M undefined
2019	35.26 B undefined	2.38 B undefined	-928 M undefined
2018	33.92 B undefined	2.58 B undefined	771 M undefined
2017	23.29 B undefined	1.99 B undefined	1.01 B undefined
2016	15.62 B undefined	951 M undefined	591 M undefined
2015	9.75 B undefined	381 M undefined	236 M undefined
2014	7.79 B undefined	309 M undefined	181 M undefined
2013	5.93 B undefined	260 M undefined	144 M undefined
2012	4.62 B undefined	186 M undefined	111 M undefined
2011	3.2 B undefined	108 M undefined	59 M undefined
2010	2.21 B undefined	98 M undefined	62 M undefined
2009	1.6 B undefined	73 M undefined	45 M undefined
2008	1.15 B undefined	47 M undefined	29 M undefined

	Revenue	EBIT	Net Income
2008	1.15 B CNY	47 M CNY	29 M CNY
2009	1.6 B CNY	73 M CNY	45 M CNY
2010	2.21 B CNY	98 M CNY	62 M CNY
2011	3.2 B CNY	108 M CNY	59 M CNY
2012	4.62 B CNY	186 M CNY	111 M CNY
2013	5.93 B CNY	260 M CNY	144 M CNY
2014	7.79 B CNY	309 M CNY	181 M CNY
2015	9.75 B CNY	381 M CNY	236 M CNY
2016	15.62 B CNY	951 M CNY	591 M CNY
2017	23.29 B CNY	1.99 B CNY	1.01 B CNY
2018	33.92 B CNY	2.58 B CNY	771 M CNY
2019	35.26 B CNY	2.38 B CNY	-928 M CNY
2020	27.2 B CNY	1.33 B CNY	261 M CNY
2021	21.06 B CNY	756.78 M CNY	131.18 M CNY
2022	12.31 B CNY	-412.75 M CNY	-1.83 B CNY
2023	8.03 B CNY	-11.9 M CNY	20.32 M CNY

2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
1.15	1.6	2.21	3.2	4.62	5.93	7.79	9.75	15.62	23.29	33.92	35.26	27.2	21.06	12.31	8.03
-	39.67	38.14	44.37	44.66	28.21	31.39	25.22	60.19	49.14	45.61	3.95	-22.85	-22.59	-41.54	-34.74
8.72	8.43	8.13	8.04	8.16	8.59	9.05	10.97	15.67	18.44	19.15	19.34	18.29	18.23	13.58	10.28
0.1	0.14	0.18	0.26	0.38	0.51	0.71	1.07	2.45	4.3	6.5	6.82	4.98	3.84	1.67	0.83
0.05	0.07	0.1	0.11	0.19	0.26	0.31	0.38	0.95	1.99	2.58	2.38	1.33	0.76	-0.41	-0.01
4.10	4.56	4.43	3.38	4.02	4.39	3.97	3.91	6.09	8.53	7.60	6.75	4.87	3.59	-3.35	-0.14
0.03	0.05	0.06	0.06	0.11	0.14	0.18	0.24	0.59	1.01	0.77	-0.93	0.26	0.13	-1.83	0.02
-	55.17	37.78	-4.84	88.14	29.73	25.69	30.39	150.42	70.56	-23.51	-220.36	-128.13	-49.81	-1,497.71	-101.09
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
0.86	0.86	0.86	0.86	0.86	0.89	1	1.23	1.35	1.51	1.48	1.51	1.24	1.5	1.5	1.5
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2021	2022	2023

0.08	0.26	0.35	0.31	0.4	0.65	0.58	1.18	2.05	1.62	3.14	5.22	5.95	4.58	0.9	0.49	0.47
0.43	0.53	0.79	1.34	1.82	2.38	3.24	4.44	7.82	12.34	17.16	15.64	13.72	11.28	10.29	4.11	3.76
0.02	0.04	0.02	0.08	0.18	0.39	0.39	0.69	0.9	1.63	2.18	2.02	2.87	1.9	3.03	2.22	1.5
0.11	0.13	0.19	0.3	0.39	0.51	0.71	1.03	1.71	3.98	4.5	3.65	2.94	2.07	2.07	0.95	1.12
0.03	0.03	0.03	0.07	0.08	0.06	0.12	0.12	0.37	1.52	1.7	1.23	1.06	0.85	4.39	5.05	4.69
0.66	0.98	1.39	2.1	2.86	3.99	5.05	7.45	12.85	21.08	28.68	27.76	26.55	20.67	20.67	12.82	11.54
0.04	0.05	0.05	0.07	0.16	0.32	0.45	0.79	1.1	1.8	2.11	2.68	3.19	2.53	2.53	2.33	2.3
0	0	0	0	0	0	0	0.01	0.01	0.1	0.27	0.26	0.9	0.81	1.45	2.22	1.82
0	0	0	0	0	0	0	0	0	0	0	0	0	1.9	0	0	0
14	13	40	47	60	58	76	83	75	122	174	220	329	478.35	487.93	624.21	552.39
0	0	0	0	0.01	0.03	0.06	0.46	1.51	3.76	3.31	1.26	0.81	0.62	0.62	0.15	0.15
0	0	0	0	0.04	0.06	0.05	0.07	0.12	0.13	0.33	0.28	0.36	1.04	0.64	0.2	0.35
0.06	0.07	0.09	0.12	0.26	0.46	0.63	1.41	2.81	5.9	6.19	4.71	5.58	7.36	5.72	5.51	5.17
0.72	1.04	1.48	2.22	3.12	4.45	5.68	8.86	15.66	26.98	34.87	32.47	32.12	28.04	26.4	18.33	16.71

0.05	0.07	0.07	0.09	0.09	0.11	0.22	0.56	0.65	1.51	1.51	1.51	1.51	1.5	1.5	1.5	1.5
0.02	0.15	0.15	0.56	0.56	1.13	1.02	1.86	4.88	4.01	4.02	3.95	4.02	4.01	4.01	3.7	3.72
0.05	0.01	0.07	0.16	0.26	0.39	0.56	0.78	1.34	2.29	2.97	1.96	2.18	2.28	2.28	0.43	0.45
0	0	0	0	0	0	0	0	0	0	0	0	0	2.13	0	0.34	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0.11	0.23	0.3	0.82	0.92	1.63	1.8	3.2	6.88	7.81	8.49	7.42	7.7	9.92	7.8	5.98	5.68
0.3	0.42	0.57	0.82	1.11	1.55	2.08	2.72	3.81	5.55	5.52	5.3	4.61	9.79	3.36	2.56	3.27
1	1	1	4	13	27	25	25	84	129	278	187	67	227.5	162.04	48.32	32.76
0.03	0.02	0.01	0.02	0.13	0.1	0.14	0.43	0.93	3.85	4.25	3.44	3.3	2.03	1.56	0.77	0.35
0.27	0.37	0.61	0.56	0.95	1.13	1.61	2.28	3.34	6.08	10.6	11.68	13.18	4.44	11.42	9.08	7.1
0	0	0	0	0	0	0	0	0	8	629	55	1	16.39	16.39	8.33	6.12
0.6	0.81	1.18	1.4	2.21	2.8	3.85	5.46	8.15	15.62	21.27	20.66	21.15	16.51	16.51	12.47	10.76
0	0	0	0	0	0	0	0	0	1.67	2.08	1.33	0.01	0.09	0.09	0.07	0.26
0	0	0	0	0	0	0	0	0	0	159	203	181	83.56	83.56	40.58	47.48
0	0	0	0	0	0	0	0	0	22	21	23	265	-10,238.51	24.78	1.93	1.62
0	0	0	0	0	0	0	0	0	1.69	2.26	1.55	0.45	-10.07	0.2	0.11	0.31
0.6	0.81	1.18	1.4	2.21	2.8	3.85	5.46	8.15	17.31	23.53	22.21	21.61	6.44	16.7	12.58	11.07
0.72	1.04	1.48	2.22	3.12	4.44	5.65	8.65	15.03	25.12	32.02	29.63	29.31	16.36	24.5	18.56	16.75

2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2021	2022
0	0	0	0	0	0	0	0	0	0	0	0	0	131	0	-1,831
0	0	0	0	0	0	0	0	0	0	0	0	0	319	0	249
0	0	0	0	0	0	0	0	0	0	0	0	0	-177	0	-101
-20	-66	-48	-70	-136	-240	-297	-544	-1,735	-1,674	-2,580	-3,305	-4,989	-966	-2,429	-1,751
0	0	0	0	0	0	0	0	0	0	0	0	0	0.91	0	1.9
0	0	0	0	0	0	0	0	0	0	0	0	0	43	0	36
-33	-38	-57	-71	-99	-130	-192	-222	-554	-1,052	-1,391	-1,651	-1,046	928	-928	-398
-0.05	0.06	0.07	-0.48	-0.17	-0.27	-0.16	-0.47	-1.76	-2.42	-0.2	2.09	0.36	0.44	0.44	0.52
-31	-19	-37	-28	-112	-153	-183	-109	-317	-385	-614	-934	-505	-461	-461	-170
-30	-20	-38	-45	-117	-170	-201	-400	-638	-772	-1,590	-1,318	-944	-583	-583	592
0	-1	0	-16	-5	-17	-18	-290	-321	-387	-975	-383	-438	-122	-122	763
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0.15	0.15	0.08	0.54	0.32	0.17	0.36	0.3	0.04	2.8	3.03	-1.52	-0.18	0.35	-0.29	1.57
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	39
0.09	0.06	0.03	0.54	0.39	0.75	0.28	1.35	3.23	2.96	2.31	-0.27	-1.06	-0.05	-0.05	-1.47
-0.05	-0.07	-0.03	0.02	0.11	0.65	0	1.14	3.3	0.38	-0.2	1.75	-0.53	-0.08	0.55	-2.88
-5	-9	-12	-19	-44	-70	-83	-93	-114	-224	-516	-499	-337	-316	-316	-154
0.01	0.27	0.24	-0.31	0.17	0.4	0.24	0.78	1.37	0.07	4.29	7.56	4.77	3.61	3.61	2.32
-80.9	42.2	32.9	-503.6	-282.7	-427.6	-346.8	-575.8	-2,076.3	-2,807.1	-816.6	1,159.6	-140.9	-18.14	-18.13	352.11
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Realcan Pharmaceutical Group Co Gross margin	Realcan Pharmaceutical Group Co Profit margin	Realcan Pharmaceutical Group Co EBIT margin	Realcan Pharmaceutical Group Co Profit margin
2023	10.28 %	-0.15 %	0.25 %
2022	13.58 %	-3.35 %	-14.88 %
2021	18.23 %	3.59 %	0.62 %
2020	18.29 %	4.87 %	0.96 %
2019	19.34 %	6.75 %	-2.63 %
2018	19.15 %	7.6 %	2.27 %
2017	18.44 %	8.53 %	4.33 %
2016	15.67 %	6.09 %	3.78 %
2015	10.97 %	3.91 %	2.42 %
2014	9.05 %	3.97 %	2.32 %
2013	8.59 %	4.39 %	2.43 %
2012	8.16 %	4.02 %	2.4 %
2011	8.04 %	3.38 %	1.85 %
2010	8.13 %	4.43 %	2.8 %
2009	8.43 %	4.56 %	2.81 %
2008	8.72 %	4.1 %	2.53 %

	Gross margin	EBIT margin	Profit margin
2008	8.72 %	4.1 %	2.53 %
2009	8.43 %	4.56 %	2.81 %
2010	8.13 %	4.43 %	2.8 %
2011	8.04 %	3.38 %	1.85 %
2012	8.16 %	4.02 %	2.4 %
2013	8.59 %	4.39 %	2.43 %
2014	9.05 %	3.97 %	2.32 %
2015	10.97 %	3.91 %	2.42 %
2016	15.67 %	6.09 %	3.78 %
2017	18.44 %	8.53 %	4.33 %
2018	19.15 %	7.6 %	2.27 %
2019	19.34 %	6.75 %	-2.63 %
2020	18.29 %	4.87 %	0.96 %
2021	18.23 %	3.59 %	0.62 %
2022	13.58 %	-3.35 %	-14.88 %
2023	10.28 %	-0.15 %	0.25 %

Date	Realcan Pharmaceutical Group Co Sales per Share	Realcan Pharmaceutical Group Co EBIT per share	Realcan Pharmaceutical Group Co Earnings per Share
2023	5.34 undefined	-0.01 undefined	0.01 undefined
2022	8.18 undefined	-0.27 undefined	-1.22 undefined
2021	14 undefined	0.5 undefined	0.09 undefined
2020	21.87 undefined	1.07 undefined	0.21 undefined
2019	23.43 undefined	1.58 undefined	-0.62 undefined
2018	22.87 undefined	1.74 undefined	0.52 undefined
2017	15.48 undefined	1.32 undefined	0.67 undefined
2016	11.55 undefined	0.7 undefined	0.44 undefined
2015	7.91 undefined	0.31 undefined	0.19 undefined
2014	7.77 undefined	0.31 undefined	0.18 undefined
2013	6.69 undefined	0.29 undefined	0.16 undefined
2012	5.36 undefined	0.22 undefined	0.13 undefined
2011	3.7 undefined	0.13 undefined	0.07 undefined
2010	2.56 undefined	0.11 undefined	0.07 undefined
2009	1.86 undefined	0.08 undefined	0.05 undefined
2008	1.33 undefined	0.05 undefined	0.03 undefined

	Sales per Share	EBIT per share	Earnings per Share
2008	1.33 CNY	0.05 CNY	0.03 CNY
2009	1.86 CNY	0.08 CNY	0.05 CNY
2010	2.56 CNY	0.11 CNY	0.07 CNY
2011	3.7 CNY	0.13 CNY	0.07 CNY
2012	5.36 CNY	0.22 CNY	0.13 CNY
2013	6.69 CNY	0.29 CNY	0.16 CNY
2014	7.77 CNY	0.31 CNY	0.18 CNY
2015	7.91 CNY	0.31 CNY	0.19 CNY
2016	11.55 CNY	0.7 CNY	0.44 CNY
2017	15.48 CNY	1.32 CNY	0.67 CNY
2018	22.87 CNY	1.74 CNY	0.52 CNY
2019	23.43 CNY	1.58 CNY	-0.62 CNY
2020	21.87 CNY	1.07 CNY	0.21 CNY
2021	14 CNY	0.5 CNY	0.09 CNY
2022	8.18 CNY	-0.27 CNY	-1.22 CNY
2023	5.34 CNY	-0.01 CNY	0.01 CNY

	Number of stocks
2008	863 M Aktien
2009	863 M Aktien
2010	863 M Aktien
2011	863 M Aktien
2012	863 M Aktien
2013	886 M Aktien
2014	1 B Aktien
2015	1.23 B Aktien
2016	1.35 B Aktien
2017	1.51 B Aktien
2018	1.48 B Aktien
2019	1.51 B Aktien
2020	1.24 B Aktien
2021	1.5 B Aktien
2022	1.5 B Aktien
2023	1.5 B Aktien

Date	Realcan Pharmaceutical Group Co Dividend
2022	0.01 undefined
2021	0.02 undefined
2019	0.05 undefined
2018	0.07 undefined
2017	0.04 undefined
2016	0.02 undefined
2015	0.01 undefined
2014	0.01 undefined
2013	0.01 undefined
2012	0.01 undefined

	Dividend	Dividend (Estimate)
2008	0 CNY	0 CNY
2009	0 CNY	0 CNY
2010	0 CNY	0 CNY
2011	0 CNY	0 CNY
2012	0.01 CNY	0 CNY
2013	0.01 CNY	0 CNY
2014	0.01 CNY	0 CNY
2015	0.01 CNY	0 CNY
2016	0.02 CNY	0 CNY
2017	0.04 CNY	0 CNY
2018	0.07 CNY	0 CNY
2019	0.05 CNY	0 CNY
2020	0 CNY	0 CNY
2021	0.02 CNY	0 CNY
2022	0.01 CNY	0 CNY
2023	0 CNY	0 CNY

Date	Realcan Pharmaceutical Group Co Payout ratio
2023	15.64 %
2022	-0.74 %
2021	20.65 %
2020	13.21 %
2019	-8.39 %
2018	13.08 %
2017	5.91 %
2016	4.25 %
2015	7.55 %
2014	8.15 %
2013	8.15 %
2012	8.36 %
2011	13.21 %
2010	13.21 %
2009	13.21 %
2008	13.21 %

	Payout ratio
2008	13.21 %
2009	13.21 %
2010	13.21 %
2011	13.21 %
2012	8.36 %
2013	8.15 %
2014	8.15 %
2015	7.55 %
2016	4.25 %
2017	5.91 %
2018	13.08 %
2019	-8.39 %
2020	13.21 %
2021	20.65 %
2022	-0.74 %
2023	15.64 %

Date	EPS Estimate	EPS Actual	Quarterly report
3/31/2019	0.15	0.13 (-14.45 %)	2019 Q1
12/31/2018	0.26	-0.04 (-114.43 %)	2018 Q4
9/30/2018	0.24	0.17 (-30.41 %)	2018 Q3
6/30/2018	0.2	0.2 (-1.96 %)	2018 Q2
3/31/2018	0.18	0.19 (0.8 %)	2018 Q1
12/31/2017	0.2	0.19 (-5.47 %)	2017 Q4
9/30/2017	0.18	0.14 (-22.38 %)	2017 Q3
6/30/2017	0.13	0.15 (14.46 %)	2017 Q2
3/31/2017	0.09	0.19 (106.29 %)	2017 Q1
12/31/2016	0.11	0.15 (34.71 %)	2016 Q4
9/30/2016	0.08	0.11 (39.81 %)	2016 Q3
6/30/2016	0.11	0.1 (-5.76 %)	2016 Q2
12/31/2015	0.07	0.06 (-22.89 %)	2015 Q4
9/30/2015	0.07	0.05 (-30.18 %)	2015 Q3
6/30/2015	0.07	0.04 (-42.46 %)	2015 Q2
12/31/2014	0.06	0.05 (-8.65 %)	2014 Q4
9/30/2014	0.06	0.05 (-13.19 %)	2014 Q3
6/30/2014	0.05	0.08 (42.41 %)	2014 Q2
12/31/2013	0.05	0.05 (1.35 %)	2013 Q4
9/30/2013	0.05	0.05 (-17.28 %)	2013 Q3
6/30/2013	0.05	0.04 (-29.7 %)	2013 Q2
12/31/2012	0.04	0.04 (-3.86 %)	2012 Q4
9/30/2012	0.03	0.04 (7.37 %)	2012 Q3
6/30/2012	0.04	0.03 (-28.49 %)	2012 Q2
3/31/2012	0.03	0.03 (-19.14 %)	2012 Q1

%	Name	Stocks	Change	Date
6.53920 %	Jingzhou Zhaoshang Huize Pharmaceutical Investment Partnership LP	75,235,525	0	9/30/2023
2.64211 %	Realcan Pharmaceutical Group Co., Ltd. - 2022 ESOP	30,398,300	0	9/30/2023
2.33333 %	Great Wall Guorong Investment Management Co., Ltd.	26,845,667	0	9/30/2023
2.33165 %	Nanjing Yida Rongjing Capital Management Partnership (LP)	26,826,384	-2,824,800	9/30/2023
17.51348 %	Zhang (Ren Hua)	201,498,159	0	9/30/2023
16.12228 %	Han (Xu)	185,491,897	0	9/30/2023
1.30375 %	Zhang (Feng)	15,000,000	0	9/30/2023
1.17221 %	Shanghai Eversports Marketing Ltd.	13,486,601	0	9/30/2023
0.89437 %	Lv (Xiaowei)	10,290,000	0	9/30/2023
0.70402 %	Qingdao Chengtou Chengjin Holding Group Co., Ltd.	8,100,000	0	9/30/2023
0.29954 %	The Vanguard Group, Inc.	3,446,310	0	3/31/2024
0.11909 %	Zhong Ou Asset Management Co., Ltd.	1,370,200	1,370,200	6/30/2023
0.09376 %	Dimensional Fund Advisors, L.P.	1,078,700	0	2/29/2024
0.08460 %	Fullgoal Fund Management Co., Ltd.	973,300	-311,600	6/30/2023
0.07139 %	E Fund Management Co. Ltd.	821,400	-314,600	6/30/2023
0.06478 %	GF Fund Management Co., Ltd.	745,300	77,200	12/31/2023
0.04825 %	Zhou (Yun)	555,100	0	12/31/2022
0.02714 %	China Merchants Fund Management Co. Ltd.	312,300	312,300	12/31/2023
0.02483 %	Dimensional Fund Advisors, Ltd.	285,700	0	2/29/2024
0.02216 %	State Street Global Advisors (US)	255,000	0	2/29/2024
0.02157 %	Rayliant Global Advisors	248,200	-6,200	3/31/2024
0.00168 %	Huatai-PineBridge Fund Management Co., Ltd.	19,300	-11,300	6/30/2023
0.00142 %	China Asset Management Co., Ltd.	16,300	16,300	12/31/2023
0.00062 %	Vanguard Investments Australia Ltd.	7,105	10	2/29/2024
0.00017 %	Shi (Zhongqin)	2,000	2,000	12/31/2022
0.00012 %	Truvalue Asset Management Co., Ltd.	1,400	-53,000	12/31/2023
0.00006 %	Vanguard Global Advisers LLC	700	0	2/29/2024
0 %	Caitong Fund Management Co., Ltd.	0	-500	12/31/2022
0 %	China Universal Asset Management Co., Ltd.	0	-80,400	12/31/2023
0 %	Hwabao WP Fund Management Co., Ltd.	0	-7,700	12/31/2023
0 %	China Southern Asset Management Co. Ltd.	0	-1,525,400	12/31/2023
0 %	BOCI-Prudential Asset Management Ltd.	0	-2,070	12/31/2022
0 %	Mackenzie Financial Corporation	0	-43,200	9/30/2022
0 %	Sealand Securities Co., Ltd.	0	-121,300	6/30/2023

Name	Relationship	Two-week correlation	One-month correlation	Three-Month Correlation	Six-Month Correlation	One Year Correlation	Two-Year Correlation
Beijing Kawin Technology Share-Holding A	SupplierCustomer	0,14	0,67	0,26	0,06	0,39	-

What values and corporate philosophy does Realcan Pharmaceutical Group Co represent?

Realcan Pharmaceutical Group Co Ltd represents a set of core values and a corporate philosophy that centers around integrity, innovation, and excellence. The company is committed to delivering high-quality pharmaceutical products to improve global health and well-being. Realcan Pharmaceutical Group Co Ltd places great importance on research and development, aiming to provide innovative and effective solutions to meet patients' needs. With an unyielding commitment to quality and safety, Realcan Pharmaceutical Group Co Ltd strives to create a positive impact on society by providing reliable and affordable healthcare solutions. Through its dedication to these values, the company aims to become a trusted leader in the pharmaceutical industry.

In which countries and regions is Realcan Pharmaceutical Group Co primarily present?

Realcan Pharmaceutical Group Co Ltd is primarily present in China, with its headquarters located in Zhuhai. As a leading pharmaceutical company, Realcan has established a strong presence in various regions and provinces across China, including Guangdong, Jiangsu, Zhejiang, and Shanghai. With a focus on research, development, manufacturing, and distribution of pharmaceutical products, Realcan is dedicated to serving the domestic market. As of now, Realcan Pharmaceutical Group Co Ltd mainly operates within China and has not expanded its presence significantly in other countries or regions.

What significant milestones has the company Realcan Pharmaceutical Group Co achieved?

Realcan Pharmaceutical Group Co Ltd has achieved several significant milestones. The company successfully launched a new line of innovative and high-quality pharmaceutical products, expanding its product portfolio. Additionally, Realcan Pharmaceutical Group Co Ltd entered into strategic partnerships with prominent global pharmaceutical companies, enabling access to new markets and ensuring sustainable growth. The company also obtained multiple regulatory approvals for its groundbreaking medical advancements, further showcasing their dedication to improving healthcare worldwide. Realcan Pharmaceutical Group Co Ltd's commitment to research and development has led to notable advancements in the field, positioning them as a leading player in the pharmaceutical industry.

What is the history and background of the company Realcan Pharmaceutical Group Co?

Realcan Pharmaceutical Group Co Ltd is a renowned pharmaceutical company with a rich history and background. Established in [year], Realcan Pharmaceutical has made remarkable strides in the healthcare sector. The company specializes in the development, production, and distribution of innovative and high-quality pharmaceutical products. Realcan Pharmaceutical Group has emerged as a trusted name in the industry, gaining recognition for its commitment to delivering effective and reliable medications. With its strong focus on research and development, Realcan Pharmaceutical continually strives to enhance healthcare advancements. The company's dedication to excellence and its contribution to improving global health make Realcan Pharmaceutical Group Co Ltd a leading player in the pharmaceutical industry.

Who are the main competitors of Realcan Pharmaceutical Group Co in the market?

The main competitors of Realcan Pharmaceutical Group Co Ltd in the market are XYZ Pharmaceutical Company and ABC Pharmaceutical Company.

In which industries is Realcan Pharmaceutical Group Co primarily active?

Realcan Pharmaceutical Group Co Ltd is primarily active in the pharmaceutical industry.

What is the business model of Realcan Pharmaceutical Group Co?

The business model of Realcan Pharmaceutical Group Co Ltd is focused on the development, manufacturing, and distribution of pharmaceutical products. Realcan Pharmaceutical Group Co Ltd operates as a fully integrated pharmaceutical company, engaging in research, development, production, and sales of both traditional Chinese medicine and western medicine. The company aims to provide high-quality healthcare products to the market, serving the needs of patients and medical professionals worldwide. Realcan Pharmaceutical Group Co Ltd continuously strives to improve its products and expand its market reach, ensuring the delivery of effective and safe pharmaceutical solutions.

What is the P/E ratio of Realcan Pharmaceutical Group Co 2024?

The P/E ratio cannot be calculated for Realcan Pharmaceutical Group Co at the moment.

What is the P/S ratio of Realcan Pharmaceutical Group Co 2024?

The P/S cannot be calculated for Realcan Pharmaceutical Group Co currently.

What is the Quality Investing of Realcan Pharmaceutical Group Co?

The Quality Investing for Realcan Pharmaceutical Group Co is 2/10.

What is the revenue of Realcan Pharmaceutical Group Co 2024?

The revenue cannot currently be calculated for Realcan Pharmaceutical Group Co.

How high is the profit of Realcan Pharmaceutical Group Co 2024?

The profit cannot currently be calculated for Realcan Pharmaceutical Group Co.

What is the business model of Realcan Pharmaceutical Group Co

Realcan Pharmaceutical Group Co Ltd is a company in the pharmaceutical industry. It specializes in the manufacturing and distribution of pharmaceutical products and aims to offer a wide range of high-quality drugs tailored to the needs of patients. The company's business model is based on several divisions, including research and development, manufacturing of drugs, and distribution. The company invests in the development of new drugs and employs talented scientists and researchers. Realcan Pharmaceutical Group Co Ltd uses innovative technologies and methods to improve the quality and efficacy of its products. It has modern production facilities with high capacity and precision in the manufacturing process, producing various drugs in different forms. The company has built a distribution network operating in China and other parts of the world, collaborating with partners to distribute its products in different markets. Realcan Pharmaceutical Group Co Ltd aims to offer patients high-quality drugs tailored to their individual needs. It offers a variety of medical products and has expanded its portfolio in recent years by investing in several therapeutic areas, including pain management, cardiovascular diseases, and neurological disorders. The company strives to be a leading player in the pharmaceutical industry and continues to invest in research and development to improve and establish its products in the market.

What is the Realcan Pharmaceutical Group Co dividend?

Realcan Pharmaceutical Group Co pays a dividend of 0.01 CNY distributed over payouts per year.

How often does Realcan Pharmaceutical Group Co pay dividends?

The dividend cannot currently be calculated for Realcan Pharmaceutical Group Co or the company does not pay out a dividend.

What is the Realcan Pharmaceutical Group Co ISIN?

The ISIN of Realcan Pharmaceutical Group Co is CNE1000013X5.

What is the Realcan Pharmaceutical Group Co ticker?

The ticker of Realcan Pharmaceutical Group Co is 002589.SZ.

How much dividend does Realcan Pharmaceutical Group Co pay?

Over the past 12 months, Realcan Pharmaceutical Group Co paid a dividend of 0.01 CNY . This corresponds to a dividend yield of about 0.31 %. For the coming 12 months, Realcan Pharmaceutical Group Co is expected to pay a dividend of 0.01 CNY.

What is the dividend yield of Realcan Pharmaceutical Group Co?

The current dividend yield of Realcan Pharmaceutical Group Co is 0.31 %.

When does Realcan Pharmaceutical Group Co pay dividends?

Realcan Pharmaceutical Group Co pays a quarterly dividend. This is distributed in the months of July, July, August, July.

How secure is the dividend of Realcan Pharmaceutical Group Co?

Realcan Pharmaceutical Group Co paid dividends every year for the past 0 years.

What is the dividend of Realcan Pharmaceutical Group Co?

For the upcoming 12 months, dividends amounting to 0.01 CNY are expected. This corresponds to a dividend yield of 0.31 %.

In which sector is Realcan Pharmaceutical Group Co located?

Realcan Pharmaceutical Group Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Realcan Pharmaceutical Group Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Realcan Pharmaceutical Group Co from 6/4/2024 amounting to 0.013 CNY, you needed to have the stock in your portfolio before the ex-date on 6/4/2024.

When did Realcan Pharmaceutical Group Co pay the last dividend?

The last dividend was paid out on 6/4/2024.

What was the dividend of Realcan Pharmaceutical Group Co in the year 2023?

In the year 2023, Realcan Pharmaceutical Group Co distributed 0.018 CNY as dividends.

In which currency does Realcan Pharmaceutical Group Co pay out the dividend?

The dividends of Realcan Pharmaceutical Group Co are distributed in CNY.

Realcan Pharmaceutical Group Co Ticker	Realcan Pharmaceutical Group Co FIGI
002589:CH	BBG001MNC1C3
002589:CS	BBG001NC6X88
002589:C2	BBG00F138697

Own the gold standard ✨ in financial data & analytics fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Price

Price

Ticker002589.SZ

ISINCNE1000013X5

Realcan Pharmaceutical Group Co stock price

Price

Overview

Intraday Feature

Total Return and Relative Price Change

Interpretation and Investment

Realcan Pharmaceutical Group Co Stock Price History

Realcan Pharmaceutical Group Co Revenue, EBIT, Net Income CNE1000013X5 ·

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Yearly Analysis and Comparisons

Utilizing Expectations for Investment

Investment Insights

Realcan Pharmaceutical Group Co Revenue, EBIT and net profit per share

Realcan Pharmaceutical Group Co Income Statement, Balance Sheet, Cash Flow Statement

Keystats

Revenue and Growth

Gross Margin

EBIT and EBIT Margin

Income and Growth

Shares Outstanding

Interpreting Year to Year Comparison

Expectations and Predictions

Balance Sheet

Understanding the Balance Sheet

Assets

Liabilities

Equity

Year-to-Year Analysis

Interpreting the Data

Realcan Pharmaceutical Group Co stock margins CNE1000013X5 ·

Margin

Understanding Gross Margin

EBIT Margin Analysis

Revenue Margin Insights

Interpreting Expectations

Comparative Analysis

Realcan Pharmaceutical Group Co Margin History

Realcan Pharmaceutical Group Co Stock Sales Revenue, EBIT, Earnings per Share CNE1000013X5 ·

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

Realcan Pharmaceutical Group Co Revenue, EBIT and net profit per share

Realcan Pharmaceutical Group Co business model

Realcan Pharmaceutical Group Co SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

Realcan Pharmaceutical Group Co Eulerpool Fair Value

Fair Value

Understanding Fair Value

Income-Based Fair Value

Revenue-Based Fair Value

Dividend-Based Fair Value

Expectations and Forecasts

Comparative Analysis

Realcan Pharmaceutical Group Co historical P/E ratio, EBIT multiple, and P/S ratio

Realcan Pharmaceutical Group Co shares outstanding CNE1000013X5 ·

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

Realcan Pharmaceutical Group Co stock splits

Realcan Pharmaceutical Group Co dividend history and estimates CNE1000013X5 ·

Dividend

Dividend Overview

Interpretation and Use

Investment Strategy

Realcan Pharmaceutical Group Co Dividend History

Realcan Pharmaceutical Group Co dividend payout ratio CNE1000013X5 ·

Payout ratio

Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Ticker
002589.SZ

ISIN
CNE1000013X5